

**Supplementary Table S4. Patient populations, subpopulations and samples used.**

Analysis		Details		n	
GEP	MMC	HM1 U133A+B HM2 U133 Plus 2.0 WBM U133 Plus 2.0		65 168 57 <b>290</b>	
		LR-group U133 Plus 2.0		<b>345</b>	
		MBC PPC HM1 U133A+B BMPC MGUS HMCL		7 7 7 7 20 <b>48</b>	
		MBC PPC BMPC MGUS HMCL		6 5 7 5 20	
		HM2 U133 Plus 2.0 MSC CD3 CD14 CD15 CD34 WBM-ND		19 5 5 5 5 7 <b>96</b>	
	other populations	HM-group		<b>779</b>	
		HM1 HM2		48	
		HM-group LR-group		120	
		HM1 HM2		345	
				<b>513</b>	
iFISH	MMC	HM1			
		HM2			
		t(4;14)		65	
		t(11;14)		65	
		11q13		56	
		1q21		53	
		17p		58	
		13q14		65	
		9q34		44	
		15q22		46	
		19q13		46	
		22q11		45	
		HM1			
		HM2			
		t(4;14)		104	
		t(11;14)		106	
		11q13		106	
		1q21		100	
		17p		105	
		13q14		108	
		9q34		58	
		15q22		62	
		19q13		73	
		22q11		48	
				<b>169</b>	
				<b>171</b>	
				<b>162</b>	
				<b>153</b>	
				<b>163</b>	
				<b>173</b>	
				<b>102</b>	
				<b>108</b>	
				<b>119</b>	
				<b>93</b>	

**Supplementary Table S4. Patient populations, subpopulations and samples used.** Heidelberg/Montpellier-group 1 (HM1), 2 (HM2) and the Little Rock (LR)-group.